| Previous Close | 0.96 |
| Open | 1.05 |
| Bid | 0.85 x 3000 |
| Ask | 1.08 x 1400 |
| Day's Range | 0.95 - 1.05 |
| 52 Week Range | 0.41 - 1.90 |
| Volume | 3,925,508 |
| Avg. Volume | 1,554,885 |
| Market Cap | 129.75M |
| Beta | 1.63 |
| PE Ratio (TTM) | -6.16 |
| EPS (TTM) | -0.16 |
| Earnings Date | May 3, 2017 - May 8, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- Zacks•2 days ago
Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares rise nearly 8% on Friday amid huge volumes.
- ACCESSWIRE•2 days ago
Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical
NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...
- PR Newswire•8 days ago
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. Synthetic Biologics intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate designed to prevent antibiotic-mediated C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR) in the gut microbiome.
